Strides Pharma Science Limited Stock Bombay S.E.

Equities

STAR

INE939A01011

Pharmaceuticals

Delayed Bombay S.E. 05:06:55 2024-04-23 am EDT 5-day change 1st Jan Change
882.4 INR +4.31% Intraday chart for Strides Pharma Science Limited +5.40% +36.12%
Sales 2024 * 41.14B 494M Sales 2025 * 45.13B 542M Capitalization 77.53B 931M
Net income 2024 * -414M -4.97M Net income 2025 * 2.92B 35.08M EV / Sales 2024 * 1.88 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.72 x
P/E ratio 2024 *
-183 x
P/E ratio 2025 *
20.8 x
Employees 2,850
Yield 2024 *
0.43%
Yield 2025 *
0.43%
Free-Float 68.29%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Strides Pharma Science Limited

1 day+4.34%
1 week+5.40%
Current month+12.78%
1 month+14.23%
3 months+35.27%
6 months+81.75%
Current year+36.12%
More quotes
1 week
826.45
Extreme 826.45
886.50
1 month
760.00
Extreme 760
886.50
Current year
644.50
Extreme 644.5
886.50
1 year
325.10
Extreme 325.1
886.50
3 years
263.45
Extreme 263.45
932.65
5 years
263.45
Extreme 263.45
1 000.00
10 years
263.45
Extreme 263.45
1 412.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 90-06-27
Director of Finance/CFO - 10-01-31
Compliance Officer - 17-02-02
Members of the board TitleAgeSince
Chief Executive Officer 63 90-06-27
Director/Board Member 80 17-05-17
Director/Board Member 63 12-07-26
More insiders
Date Price Change Volume
24-04-23 882.4 +4.31% 34 571
24-04-22 845.9 +0.34% 10,651
24-04-19 843 -0.12% 26,553
24-04-18 844 +0.79% 10,676
24-04-16 837.4 +1.25% 7,013

Delayed Quote Bombay S.E., April 23, 2024 at 05:06 am EDT

More quotes
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
843.6 INR
Average target price
830.5 INR
Spread / Average Target
-1.55%
Consensus

Quarterly revenue - Rate of surprise